Topics

Alpha 2C Adrenergic Receptor Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

11:39 EST 11 Feb 2020 | BioPortfolio Report Blog

Alpha 2C Adrenergic Receptor Pipeline Review, H2 2019


Summary


Alpha 2C Adrenergic Receptor Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C Alpha2C adrenergic receptor or ADRA2C is an alpha2 adrenergic receptor. It mediates the catecholamineinduced inhibition of adenylate cyclase through the action of G proteins. This receptor plays a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system.


Alpha 2C Adrenergic Receptor Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C pipeline Target constitutes close to 6 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 1 respectively. Report covers products from therapy areas Central Nervous System and Cardiovascular which include indications Schizophrenia, Alzheimer's Disease, Bipolar Disorder Manic Depression, Cognitive Disorders, Dementia Associated With Alzheimer's Disease, Depression, Generalized Anxiety Disorder GAD, Major Depressive Disorder, Peripheral Arterial Disease PAD/ Peripheral Vascular Disease PVD, Pervasive Developmental Disorder PDD, PostTraumatic Stress Disorder PTSD and Psychiatric Disorders.


The latest report Alpha 2C Adrenergic Receptor Pipeline Review, H2 2019, outlays comprehensive information on the Alpha 2C Adrenergic Receptor Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Alpha 2C Adrenergic Receptor Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C targeted therapeutics development with respective active and dormant or discontinued projects.


The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Scope


The report provides a snapshot of the global therapeutic landscape for Alpha 2C Adrenergic Receptor Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C

The report reviews Alpha 2C Adrenergic Receptor Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Alpha 2C Adrenergic Receptor Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C targeted therapeutics and enlists all their major and minor projects

The report assesses Alpha 2C Adrenergic Receptor Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Alpha 2C Adrenergic Receptor Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Alpha 2C Adrenergic Receptor Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alpha 2C Adrenergic Receptor Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Alpha 2C Adrenergic Receptor Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975

NEXT ARTICLE

More From BioPortfolio on "Alpha 2C Adrenergic Receptor Pipeline Review, H2 2019 [Published by Global Markets Direct] Prices from USD $2975"

Quick Search

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...